MAPT and Alzheimer disease: Although abnormal levels of Aβ are now typically among inclusion criteria for AD clinical trials,118, 119 and results from anti‐amyloid trials have suggested that it will be important to recruit individuals at earlier stages of Aβ accumulation, less attention has been given to levels of tau accumulation in clinical trial recruitment.